These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

178 related articles for article (PubMed ID: 35738174)

  • 21. Integrated docking and enhanced sampling-based selection of repurposing drugs for SARS-CoV-2 by targeting host dependent factors.
    Kumawat A; Namsani S; Pramanik D; Roy S; Singh JK
    J Biomol Struct Dyn; 2022; 40(20):9897-9908. PubMed ID: 34155961
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Developing a SARS-CoV-2 main protease binding prediction random forest model for drug repurposing for COVID-19 treatment.
    Liu J; Xu L; Guo W; Li Z; Khan MKH; Ge W; Patterson TA; Hong H
    Exp Biol Med (Maywood); 2023 Nov; 248(21):1927-1936. PubMed ID: 37997891
    [TBL] [Abstract][Full Text] [Related]  

  • 23. In silico evaluation of Philippine Natural Products against SARS-CoV-2 Main Protease.
    Cheng AJT; Macalino SJY; Billones JB; Balolong MP; Murao LAE; Carrillo MCO
    J Mol Model; 2022 Oct; 28(11):345. PubMed ID: 36205801
    [TBL] [Abstract][Full Text] [Related]  

  • 24. In Silico Drug Repositioning to Target the SARS-CoV-2 Main Protease as Covalent Inhibitors Employing a Combined Structure-Based Virtual Screening Strategy of Pharmacophore Models and Covalent Docking.
    Vázquez-Mendoza LH; Mendoza-Figueroa HL; García-Vázquez JB; Correa-Basurto J; García-Machorro J
    Int J Mol Sci; 2022 Apr; 23(7):. PubMed ID: 35409348
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Can natural products stop the SARS-CoV-2 virus? A docking and molecular dynamics study of a natural product database.
    Novak J; Rimac H; Kandagalla S; Grishina MA; Potemkin VA
    Future Med Chem; 2021 Feb; 13(4):363-378. PubMed ID: 33415989
    [No Abstract]   [Full Text] [Related]  

  • 26. Natural Products-Based Drug Design against SARS-CoV-2 Mpro 3CLpro.
    Silva RC; Freitas HF; Campos JM; Kimani NM; Silva CHTP; Borges RS; Pita SSR; Santos CBR
    Int J Mol Sci; 2021 Oct; 22(21):. PubMed ID: 34769170
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Different compounds against Angiotensin-Converting Enzyme 2 (ACE2) receptor potentially containing the infectivity of SARS-CoV-2: an in silico study.
    Shahbazi B; Mafakher L; Teimoori-Toolabi L
    J Mol Model; 2022 Mar; 28(4):82. PubMed ID: 35249180
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Repurposing potential of FDA-approved and investigational drugs for COVID-19 targeting SARS-CoV-2 spike and main protease and validation by machine learning algorithm.
    Verma AK; Aggarwal R
    Chem Biol Drug Des; 2021 Apr; 97(4):836-853. PubMed ID: 33289334
    [TBL] [Abstract][Full Text] [Related]  

  • 29.
    Xie S; Cao S; Wu J; Xie Z; Liu YT; Fu W; Zhao Q; Liu L; Yang L; Li J
    J Biomol Struct Dyn; 2024 Jul; 42(10):5229-5237. PubMed ID: 37349935
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Exploring epigenetic drugs as potential inhibitors of SARS-CoV-2 main protease: a docking and MD simulation study.
    Uzuner U; Akkus E; Kocak A; Çelik Uzuner S
    J Biomol Struct Dyn; 2024 Aug; 42(13):6892-6903. PubMed ID: 37458994
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Identifying the natural polyphenol catechin as a multi-targeted agent against SARS-CoV-2 for the plausible therapy of COVID-19: an integrated computational approach.
    Mishra CB; Pandey P; Sharma RD; Malik MZ; Mongre RK; Lynn AM; Prasad R; Jeon R; Prakash A
    Brief Bioinform; 2021 Mar; 22(2):1346-1360. PubMed ID: 33386025
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Targeting SARS-CoV-2 RNA-dependent RNA polymerase: An
    Baby K; Maity S; Mehta CH; Suresh A; Nayak UY; Nayak Y
    F1000Res; 2020; 9():1166. PubMed ID: 33204411
    [No Abstract]   [Full Text] [Related]  

  • 33. Computational repurposing approach for targeting the critical spike mutations in B.1.617.2 (delta), AY.1 (delta plus) and C.37 (lambda) SARS-CoV-2 variants using exhaustive structure-based virtual screening, molecular dynamic simulations and MM-PBSA methods.
    Ebrahimi M; Karami L; Alijanianzadeh M
    Comput Biol Med; 2022 Aug; 147():105709. PubMed ID: 35728285
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Repurposing simeprevir, calpain inhibitor IV and a cathepsin F inhibitor against SARS-CoV-2 and insights into their interactions with M
    J A; Francis D; C S S; K G A; C S; Variyar EJ
    J Biomol Struct Dyn; 2022 Jan; 40(1):325-336. PubMed ID: 32873185
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Repurposing of antimycobacterium drugs for COVID-19 treatment by targeting SARS CoV-2 main protease: An in-silico perspective.
    Chakraborty A; Ghosh R; Soumya Mohapatra S; Barik S; Biswas A; Chowdhuri S
    Gene; 2024 Sep; 922():148553. PubMed ID: 38734190
    [TBL] [Abstract][Full Text] [Related]  

  • 36. In silico Drug Repurposing for COVID-19: Targeting SARS-CoV-2 Proteins through Docking and Consensus Ranking.
    Cavasotto CN; Di Filippo JI
    Mol Inform; 2021 Jan; 40(1):e2000115. PubMed ID: 32722864
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Structure based Drug Designing Approaches in SARS-CoV-2 Spike Inhibitor Design.
    Shanmugam A; Venkattappan A; Gromiha MM
    Curr Top Med Chem; 2022; 22(29):2396-2409. PubMed ID: 36330617
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Drug repurposing for identification of potential spike inhibitors for SARS-CoV-2 using molecular docking and molecular dynamics simulations.
    Lazniewski M; Dermawan D; Hidayat S; Muchtaridi M; Dawson WK; Plewczynski D
    Methods; 2022 Jul; 203():498-510. PubMed ID: 35167916
    [TBL] [Abstract][Full Text] [Related]  

  • 39. A multi-stage virtual screening of FDA-approved drugs reveals potential inhibitors of SARS-CoV-2 main protease.
    Mandour YM; Zlotos DP; Alaraby Salem M
    J Biomol Struct Dyn; 2022 Mar; 40(5):2327-2338. PubMed ID: 33094680
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Virtual high throughput screening: Potential inhibitors for SARS-CoV-2 PL
    Jade D; Ayyamperumal S; Tallapaneni V; Joghee Nanjan CM; Barge S; Mohan S; Nanjan MJ
    Eur J Pharmacol; 2021 Jun; 901():174082. PubMed ID: 33823185
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.